The Conversation (0)
Avinger Announces Closing of $18 Million Underwritten Public Offering
Feb. 19, 2018 08:46AM PST
Medical Device InvestingAvinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the closing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of approximately $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger. As quoted in the press …
Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the closing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of approximately $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger.
As quoted in the press release:
The company intends to use the net proceeds from this offering for working capital and general corporate purposes, and may also use a portion of the net proceeds to resolve pending legal proceedings.
